by Agastiya Biotech | Apr 3, 2024 | Media
Vopec Pharmaceuticals and Agastiya Biotech Announce Breakthrough Phase 1 Study Results of Small Molecule AB001 for Multiple Metastatic Solid Tumors Vopec Pharmaceuticals and Agastiya Biotech today announced topline results from the Phase 1 study of AB001, an...
by Agastiya Biotech | May 3, 2022 | Media
Agastiya Biotech and Vopec Pharmaceuticals announce that the US FDA has granted Orphan Drug Designations for Pancreatic Cancer and AML for its novel small molecule, AB001. AB001 is a small molecule PD-L1 checkpoint inhibitor that also targets aberrant intracellular...
by Agastiya Biotech | Jan 19, 2022 | Media
Agasitya BiotechIntroducing Quantum Medicine to the World Agastiya Biotech is not another biotech company following the conventional drug discovery and therapeutic models practiced by Western biotech companies. How is Agastiya different from contemporary...
by Agastiya Biotech | Apr 24, 2020 | Media
SAN DIEGO–(BUSINESS WIRE)–Agastiya Biotech LLC (www.agastiyabiotech.com) today announces it has discovered its previously tested anti-cancer small molecule AB001 as a viable SARS-CoV-2 virus therapeutic. Based on in silico models, AB001 acts on ACE-2 to...
by Agastiya Biotech | Mar 26, 2020 | Media
Vopec Pharmaceuticals has received the NOC (no objection certificate) and license to develop and test its new anti cancer drug as a new chemical entity (NCE), which also offers a promising therapeutic option for COVID-19. It inhibits Angiotensin-converting enzyme-2...
by Agastiya Biotech | Feb 20, 2020 | Media
Vopec Pharma and East-West Integrative Research Institute, both based in Chennai India, have received funds and know-how from Agastiya Biotech to develop drugs for Stage IV cancer and COViD-19. Baskaran Pillai PhD., founded Agastiya Biotech with a vison to integrate...
Recent Comments